Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.78 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.78 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.69 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.69 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.69 |
| ▸ | TSPO | P30536 | 1/20 | 0.69 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.69 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.50 |
| ▸ | P2RY10 | O00398 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | GMNN | O75496 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | CETP | P11597 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sphingosylphosphorylchloline SCHEMBL12513601 | 1.00 | MEN1 (0.78) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| Sphingosylphosphorylchloline SCHEMBL196291 | 0.99 | MEN1 (0.77) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| Sphingosylphosphorylchloline SCHEMBL195873 | 0.99 | MEN1 (0.77) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| SCHEMBL17696724 | 0.90 | S1PR1 (0.77) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| SCHEMBL17775054 | 0.88 | S1PR1 (0.62) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| Sphingosylphosphorylchloline SCHEMBL195431 | 0.88 | S1PR1 (1.00) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| Sphingosylphosphorylchloline SCHEMBL19928025 | 0.88 | S1PR1 (1.00) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| SCHEMBL31427625 | 0.88 | S1PR1 (1.00) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| SCHEMBL29602895 | 0.87 | S1PR1 (0.73) | MEN1KMT2AS1PR1S1PR4S1PR3 | |
| SCHEMBL14095793 | 0.85 | S1PR1 (0.58) | MEN1KMT2AS1PR1S1PR4S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230088528-A1 | USE OF LIPID IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT THEREOF | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2023-03-23 | — | — | US | claimed |
| EP-4056552-A1 | USE OF LIPID IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT THEREOF | Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CN) | 2022-09-14 | — | — | EP | claimed |
| CN-104894058-B | Sphingosylphosphocholine is preparing the application that rush endogenous heart stem cell is divided into cardiac linage cell drug | 山东大学 | 2017-10-27 | — | — | CN | claimed |
| CN-106170302-A | Drug delivery accelerator containing the material making Lysophospholipid Receptor activate | 国立大学法人大阪大学 | 2016-11-30 | — | — | CN | claimed |
| CN-105287608-A | Application of sphingosylphosphorylcholine in preparing anti-breast cancer drugs | UNIV SHANDONG | 2016-02-03 | — | — | CN | claimed |
| CN-104894058-A | Application of sphingosylphosphorylcholine (SPC) in preparation of medicine for promoting endogenesis heart stem cells to be differentiated into heart lineage cells | UNIV SHANDONG | 2015-09-09 | — | — | CN | claimed |
| CN-101443347-A | Use of sphingosylphosphorylcholine antagonist for restoring the expression of antimicrobial peptides | AMOREPACIFIC CORP (KR) | 2009-05-27 | — | — | CN | claimed |
| US-20070238668-A1 | Methods of using gelsolin to treat or prevent bacterial sepsis | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2007-10-11 | — | — | US | claimed |
| US-5830432-A | Phospholipid drug derivatives | AMUR PHARMACUTICALS, INC. (US) | 1998-11-03 | — | — | US | claimed |
| US-5464740-A | Diagnositc agent and methods for identifying HIV infected individuals and monitoring their therapy | AMUR RESEARCH CORP. (US) | 1995-11-07 | — | — | US | claimed |
| CN-118406754-B | LacCer and application of its synthetase in NAFLD-based AILI evaluation and treatment | 上海交通大学医学院附属仁济医院 | 2026-05-22 | — | — | CN | disclosed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260072045-A1 | METHOD FOR DETECTING LYSOSOMAL STORAGE DISEASE BIOMARKERS AND KITS FOR PERFORMING THE METHOD | UNIVERSITEIT ANTWERPEN (BE) | 2026-03-12 | — | — | US | disclosed |
| US-20260063601-A1 | PLASMA METABOLOME AS A PREDICTOR OF BIOLOGICAL AGING | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY (US) | 2026-03-05 | — | — | US | disclosed |
| US-12509444-B2 | Compounds and methods for CD73 modulation and indications therefor | PLEXXIKON INC. (US) | 2025-12-30 | — | — | US | disclosed |
| WO-1997001752-A1 | METHOD FOR QUANTIFYING SPHINGOSINE AND FOR DIAGNOSING PLATELET ACTIVATION | ONCOMEMBRANE, INC. (US) | 1997-01-16 | — | — | WO | disclosed |
| EP-0671917-A1 | METHOD FOR INHIBITION OF CELL MOTILITY BY SPHINGOSINE-1-PHOSPHATE, ITS DERIVATIVES AND MIMETICS AND METHOD OF SYNTHESIZING SPHINGOSINE-1-PHOSPHATE AND ITS DERIVATIVES | ONCOMEMBRANE, INC. (US) | 1995-09-20 | — | — | EP | disclosed |
| US-5391800-A | Protecting hydroxyl groups of sphingosine, deprotecting C1, phosphorylating, deprotecting C3; free of L-threo isomer | THE BIOMEMBRANE INSTITUTE (US) | 1995-02-21 | — | — | US | disclosed |
| US-5260288-A | Administering an inflammation inhibitory amount | THE BIOMEMBRANE INSTITUTE (US) | 1993-11-09 | — | — | US | disclosed |
| WO-1993019760-A1 | METHOD FOR INHIBITION OF CELL MOTILITY BY SPHINGOSINE-1-PHOSPHATE, ITS DERIVATIVES AND MIMETICS AND METHOD OF SYNTHESIZING SPHINGOSINE-1-PHOSPHATE AND ITS DERIVATIVES | THE BIOMEMBRANE INSTITUTE (US) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260063601-A1 | PLASMA METABOLOME AS A PREDICTOR OF BIOLOGICAL AGING | PLPBP, PLCG1, PLA2G1B | MEN1 1962/4885KMT2A 3526/4885S1PR1 54/4885 |
| US-20230088528-A1 | USE OF LIPID IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT THEREOF | NPC1L1, LIPA, NPC1 | MEN1 2917/4885KMT2A 1426/4885S1PR1 429/4885 |
| US-20260072045-A1 | METHOD FOR DETECTING LYSOSOMAL STORAGE DISEASE BIOMARKERS AND KITS FOR PERFORMING THE METHOD | GBA1, GBA2, MAN2B1 | MEN1 3719/4885KMT2A 2702/4885S1PR1 130/4885 |
| US-12509444-B2 | Compounds and methods for CD73 modulation and indications therefor | ENTPD5, ADORA1, ADORA2A | MEN1 1556/4885KMT2A 3779/4885S1PR1 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.